Yungjin Pharm. Co., Ltd. (KRX:003520)

South Korea · Delayed Price · Currency is KRW

1,285.00

+14.00 (1.10%)

Jun 16, 2026, 3:30 PM KST

-40.92% (1Y)

Market Cap	235.02B -40.8%
Revenue (ttm)	158.79B +23.4%
Net Income	8.53B +1,006.9%
EPS	53.49 +1,199.6%
Shares Out	182.89M
PE Ratio	24.02
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	245,523
Open	1,270.00
Previous Close	1,271.00
Day's Range	1,260.00 - 1,302.00
52-Week Range	1,203.00 - 2,450.00
Beta	0.63
Analysts	n/a
Price Target	2,966.65 (+130.87%)
Earnings Date	n/a

About Yungjin Pharm.

Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. The company offers cephalosporin antibiotic, antipsychotic, cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, anti-inflammatory and analgesics, nutritional supplement, and urology products. It also provides vitamins, minerals, and other products; and APIs. The company was founded in 1952 and is headquartered in Seoul, South Korea. Yungjin Pharm. Co., Ltd. operates as a subsidiary of KT&G Corporation. [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1952

Employees 574

Stock Exchange Korea Stock Exchange

Ticker Symbol 003520

Full Company Profile

Financial Performance

In 2012, Yungjin Pharm.'s revenue was 137.69 billion, an increase of 22.82% compared to the previous year's 112.11 billion. Earnings were 1.79 billion, a decrease of -30.48%.

Financial Statements